Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
PEPG
PEPG | US
1.69
USD0
0%
PEPG | US
About PEPG
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
14/04/2026
Close
1.69
Open
1.73
High
1.80
Low
1.68
PepGen Inc. a clinical-stage biotechnology company focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51 an EDO peptide that id in Phase I clinical trial to treat individuals with Duchenne muscular dystrophy (DMD). The company is also developing PGN-EDODM1 an EDO peptide-conjugated PMO which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1 as well as EDO therapeutic candidates such as PGN-EDO53 PGN-EDO45 and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is headquartered in Boston Massachusetts.
View LessPEPG | US
Risk
205.5
Sharpe
0.23
Luna's Score
43/100
Recommendation
Sell
Luna says (PEPG | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
What's not Working
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
295.4%1 month
205.5%3 months
155.0%6 months
130.3%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
1.88
Debt to equity
0.13
Debt to assets
0.10
Ent. to EBITDA
-3.11
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-94.36M
MarketCap
55.08M
MarketCap(USD)
55.08M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-58.97
Short ratio
7.73
Short perc.
5.64
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
0.76
Range1M
4.18
Range3M
5.82
Volumes: Market Activity
Rel. volume
0.49
Price X volume
1.93M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -3.11 | - | Cheaper |
| Ent. to Revenue | - | - | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 1.88 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 155.03 | - | Riskier |
| Debt to Equity | 0.13 | -1.23 | Expensive |
| Debt to Assets | 0.10 | 0.25 | Cheaper |
| Market Cap | 55.08M | - | Emerging |
